Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer

Pancreas. 2011 Aug;40(6):983-4. doi: 10.1097/MPA.0b013e3182164002.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Capecitabine
  • Cisplatin / administration & dosage
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Disease-Free Survival
  • Epirubicin / administration & dosage
  • Fluorouracil / administration & dosage
  • Fluorouracil / analogs & derivatives
  • Gemcitabine
  • Humans
  • Infusions, Intra-Arterial
  • Pancreatic Neoplasms / drug therapy*
  • Prospective Studies
  • Survival Analysis
  • Treatment Failure

Substances

  • Deoxycytidine
  • Epirubicin
  • Capecitabine
  • Cisplatin
  • Fluorouracil
  • Gemcitabine